We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Silencing the HMGA1 Gene Blocks Metastasis in Breast Cancer

By LabMedica International staff writers
Posted on 15 May 2013
Blocking the activity of the protein encoded by the HMGA1 (high mobility group A1) gene in breast cancer cells renders them less aggressive and diminishes their ability to metastasize.

Investigators at Johns Hopkins University (Baltimore, MD, USA) have been studying the role of HMGA1 in cancer growth and spread for more than 20 years. More...
In the current paper, they described experiments with "triple negative" breast cancer cells—those that lack hormone receptors or HER2 gene amplification—in which HMGA1 expression had been silenced.

They reported in the May 2, 2013, online edition of the journal PLOS ONE that silencing HMGA1 expression in the aggressive, invasive triple negative breast cancer cells dramatically halted cell growth and resulted in striking morphologic changes from mesenchymal-like, spindle-shaped cells to cuboidal, epithelial-like cells. Mesenchymal genes were repressed, while E-cadherin was induced in the cells that lacked HMGA1 expression. Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin down regulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.






Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.